Esketamine

Medical uses

Anesthesia

Esketamine is used for similar indications as ketamine. Such uses include induction of anesthesia in high-risk patients such as those with circulatory shock, severe bronchospasm, or as a supplement to regional anesthesia with incomplete nerve blocks.

Depression

In the US, esketamine (brand name Spravato) is a nasal spray indicated, as monotherapy, or in conjunction with an oral antidepressant as a therapy for treatment-resistant depression (TRD) as well as major depressive disorder (MDD) associated with suicidal ideation or behavior in adults. In the clinical trials that led to approval of esketamine, treatment-resistant depression was defined as major depressive disorder with inadequate response to at least two different conventional antidepressants. The nasal spray formulation of esketamine used for depression delivers two sprays containing a total of 28 mg esketamine and doses of 56 mg (2 devices) to 84 mg (3 devices) are used. Due to concerns about sedation, dissociation, and misuse, esketamine is available for treatment of depression only from certified providers through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called Spravato REMS.

Five clinical studies of esketamine for treatment-resistant depression (TRANSFORM-1, -2, and -3, and SUSTAIN-1 and -2) were submitted to and evaluated by the FDA when approval of esketamine for treatment of treatment-resistant depression was sought by Janssen Pharmaceuticals. Of these five studies, three were short-term (4-week) efficacy studies (the TRANSFORM studies). Two of these three studies (TRANSFORM-1 and -3) did not find a statistically significant antidepressant effect of esketamine relative to placebo. In the one positive short-term efficacy study (TRANSFORM-2), there was a 4.0-point difference between esketamine and placebo on the Montgomery–Åsberg Depression Rating Scale (MADRS) after 4 weeks of treatment (P = 0.020). This scale ranges from 0 to 60 and the average score of the participants at the start of the study was about 37.0 in both the esketamine and placebo groups. The total change in score after 4 weeks was –19.8 points in the esketamine group and –15.8 points in the placebo group. This corresponded to a percentage change in MADRS score from baseline of –53.5% with esketamine and –42.4% with placebo (a difference and reduction of depression score of –11.1% potentially attributable to the pharmacological action of esketamine) in these patient samples. Placebo showed 80.0% of the antidepressant effect of esketamine for treatment-resistant depression in this study, and hence approximately 20.0% of the antidepressant response was attributable to esketamine. In the two negative short-term efficacy trials that did not reach statistical significance (TRANSFORM-1 and -3), the differences in MADRS reductions between esketamine and placebo were –3.2 (P = 0.088) and –3.6 (P = 0.059) after 4 weeks of treatment.

The 4.0-point additional reduction in MADRS score with esketamine over placebo in the single positive efficacy trial corresponds to less than "minimal improvement" and has been criticized as being below the threshold for clinically meaningful change. A difference of at least 6.5 points was originally suggested by the trial investigators to be a reasonable threshold for clinical significance. In other literature, MADRS reductions have been interpreted as "very much improved" corresponding to 27–28 points, "much improved" to 16–17 points, and "minimally improved" to 7–9 points. It has additionally been argued that the small advantage in scores with esketamine may have been related to an enhanced placebo response in the esketamine group due to functional unblinding caused by the psychoactive effects of esketamine. In other words, it is argued that the study was not truly a double-blind controlled trial. Dissociation was experienced as a side effect by a majority of participants who received esketamine (61–75% with esketamine and 5–12% with placebo; ~7-fold difference) and "severe" dissociation was experienced by 25%. Deblinding and expectancy confounds are problems with studies of hallucinogens for psychiatric indications in general. The FDA normally requires at least two positive short-term efficacy studies for approval of antidepressants, but this requirement was loosened for esketamine and a relapse-prevention trial was allowed to fill the place of the second efficacy trial instead. This is the first time that the FDA is known to have made such an exception and the decision has been criticized as lowering regulatory standards. In the relapse-prevention trial (SUSTAIN-2), the rate of depression relapse was significantly lower with esketamine continued than with it discontinued and replaced with placebo in esketamine-treated stable responders and remitters (51% rate reduction in remitters and 70% reduction in responders).

Esketamine was approved for the treatment of major depressive disorder with co-occurring suicidal ideation or behavior based on two short-term (4-week) phase 3 trials (ASPIRE-1 and -2) of esketamine nasal spray added to a conventional antidepressant. The primary efficacy measure was reduction in MADRS total score after 24 hours following the first dose of esketamine. In both trials, MADRS scores were significantly reduced with esketamine relative to placebo at 24 hours. The mean MADRS scores at baseline were 39.4 to 41.3 in all groups, and the MADRS reductions at 24 hours were –15.9 and –16.0 with esketamine and –12.0 and –12.2 with placebo, resulting in mean differences between esketamine and placebo of –3.8 and –3.9. The secondary efficacy measure in the trials was change in Clinical Global Impression of Suicidal Severity - Revised (CGI-SS-r) 24 hours after the first dose of esketamine. The CGI-SS-r is a single-item scale with scores ranging from 0 to 6. Esketamine was not significantly effective in reducing suicidality relative to placebo on this measure either at 24 hours or after 25 days. At 24 hours, CGI-SS-r scores were changed by –1.5 with esketamine and –1.3 with placebo, giving a non-significant mean difference between esketamine and placebo of –0.20. Hence, while efficacious in reducing depressive symptoms in people with depression and suicidality, antisuicidal effects of esketamine in such individuals have not been demonstrated.

Expectations were initially very high for ketamine and esketamine for treatment of depression based on early small-scale clinical studies, with discovery of the rapid and ostensibly robust antidepressant effects of ketamine described by some authors as "the most important advance in the field of psychiatry in the past half century". According to a 2018 review, ketamine showed more than double the antidepressant effect size over placebo of conventional antidepressants in the treatment of depression based on the preliminary evidence available at the time (Cohen's d = 1.3–1.7 for ketamine, Cohen's d = 0.8 for midazolam (active placebo), and Cohen's d = 0.53–0.81 for conventional antidepressants). However, the efficacy of ketamine/esketamine for depression declined dramatically as studies became larger and more methodologically rigorous. The effectiveness of esketamine for the indication of treatment-resistant depression is described as "modest" and is similar in magnitude to that of other antidepressants for the treatment of major depressive disorder. The comparative effectiveness of ketamine and esketamine in the treatment of depression has not been adequately characterized. A January 2021 meta-analysis reported that ketamine was similarly effective to esketamine in terms of antidepressant effect size ( for depression score of –1.1 vs. –1.2) but more effective than esketamine in terms of response and remission rates ( = 3.01 vs. RR = 1.38 for response and RR = 3.70 vs. RR = 1.47 for remission). A September 2021 Cochrane review found that ketamine had an effect size (SMD) for depression at 24hours of –0.87, with very low certainty, and that esketamine had an effect size (SMD) at 24hours of –0.31, based on moderate-certainty evidence. However, these meta-analyses have involved largely non-directly comparative studies with dissimilar research designs and patient populations. Only a single clinical trial has directly compared ketamine and esketamine for depression as of May 2021. This study reported similar antidepressant efficacy as well as tolerability and psychotomimetic effects between the two agents. However, the study was small and underpowered, and more research is still needed to better-characterize the comparative antidepressant effects of ketamine and esketamine. Preliminary research suggests that arketamine, the R(−) enantiomer of ketamine, may also have its own independent antidepressant effects and may contribute to the antidepressant efficacy of racemic ketamine, but more research likewise is needed to evaluate this possibility.

In February 2019, an outside panel of experts recommended in a 14–2 vote that the FDA approve the nasal spray version of esketamine for treatment-resistant depression, provided that it be given in a clinical setting, with people remaining on site for at least two hours after. The reasoning for this requirement is that trial participants temporarily experienced sedation, visual disturbances, trouble speaking, confusion, numbness, and feelings of dizziness during immediately after. The approval of esketamine for treatment-resistant depression by the FDA was controversial due to limited and mixed evidence of efficacy and safety. In January 2020, esketamine was rejected by the National Health Service (NHS) of Great Britain. The NHS questioned the benefits of the medication for depression and claimed that it was too expensive. People already using esketamine were allowed to complete treatment if their doctors considered this necessary.

Spravato debuted at a cost of treatment of per year when it launched in the United States in March 2019. The Institute for Clinical and Economic Review (ICER), which evaluates cost effectiveness of drugs analogously to the National Institute for Health and Care Excellence (NICE) in the United Kingdom, declined to recommend esketamine for depression due to its steep cost and modest efficacy, deeming it not sufficiently cost-effective.

Esketamine is the second drug to be approved for treatment-resistant depression by the FDA, following olanzapine/fluoxetine (Symbyax) in 2009. Other agents, like the atypical antipsychotics aripiprazole (Abilify) and quetiapine (Seroquel), have been approved for use in the adjunctive therapy of major depressive disorder in people with a partial response to treatment. In a meta-analysis conducted internally by the FDA during its evaluation of esketamine for treatment-resistant depression, the FDA reported a standardized mean difference (SMD) of esketamine for treatment-resistant depression of 0.28 using the three phase III short-term efficacy trials conducted by Janssen. This was similar to an SMD of 0.26 for olanzapine/fluoxetine for treatment-resistant depression and lower than SMDs of 0.35 for aripiprazole and 0.40 for quetiapine as adjuncts for major depressive disorder. These drugs are less expensive than esketamine and may serve as more affordable alternatives to it for depression with similar effectiveness.

Adverse effects

Main article: Ketamine#Adverse effects

The most common adverse effects of esketamine for depression (≥5% incidence) include dissociation, dizziness, sedation, nausea, vomiting, vertigo, numbness, anxiety, lethargy, increased blood pressure, and feelings of drunkenness. Long-term abuse of ketamine has been associated with bladder disease.

Pharmacology

Pharmacodynamics

Esketamine is approximately twice as potent an anesthetic as racemic ketamine.

In mice, the rapid antidepressant effect of arketamine was greater and lasted longer than that of esketamine. The usefulness of arketamine over esketamine has been supported by other researchers.

Esketamine inhibits dopamine transporters eight times more than arketamine. This increases dopamine activity in the brain. At doses causing the same intensity of effects, esketamine is generally considered to be more pleasant by patients. Patients also generally recover mental function more quickly after being treated with pure esketamine, which may be a result of the fact that it is cleared from their system more quickly. This is however in contradiction with arketamine being devoid of psychotomimetic side effects.

Unlike arketamine, esketamine does not bind significantly to sigma receptors. Esketamine increases glucose metabolism in the frontal cortex, while arketamine decreases glucose metabolism in the brain. This difference may be responsible for the fact that esketamine generally has a more dissociative or hallucinogenic effect while arketamine is reportedly more relaxing. However, another study found no difference between racemic ketamine and esketamine on the patient's level of vigilance. Interpretation of this finding is complicated by the fact that racemic ketamine is 50% esketamine.

Pharmacokinetics

Esketamine is eliminated from the human body more quickly than arketamine (R(–)-ketamine) or racemic ketamine, although arketamine slows the elimination of esketamine. The half-life of esketamine was found to be approximately 5 hours. When administered intranasally, esketamine's bioavailability is approximately 30–50%.

Chemistry

Esketamine is the (S)-enantiomer of ketamine, which is a racemic mixture of esketamine and arketamine ((R)-ketamine).

History

Esketamine was introduced for medical use as an anesthetic in Germany in 1997, and was subsequently marketed in other countries. In addition to its anesthetic effects, the medication showed properties of being a rapid-acting antidepressant, and was subsequently investigated for use as such. Esketamine received a breakthrough designation from the for treatment-resistant depression (TRD) in 2013 and major depressive disorder (MDD) with accompanying suicidal ideation in 2016. In November 2017, it completed phase III clinical trials for treatment-resistant depression in the United States. Johnson & Johnson filed a Food and Drug Administration (FDA) New Drug Application (NDA) for approval on 4 September 2018; the application was endorsed by an FDA advisory panel on 12 February 2019, and on 5 March 2019, the FDA approved esketamine, in conjunction with an oral antidepressant, for the treatment of depression in adults. In August 2020, it was approved by the U.S. Food and Drug Administration (FDA) with the added indication for the short-term treatment of suicidal thoughts.

Since the 1980s, closely associated ketamine has been used as a club drug also known as "Special K" for its trip-inducing side effects.

Society and culture

Names

Esketamine is the generic name of the drug and its and , while esketamine hydrochloride is its . It is also known as S(+)-ketamine, (S)-ketamine, or (–)-ketamine ((-)[+] ketamine), as well as by its developmental code name JNJ-54135419.

Esketamine is sold under the brand name Spravato for use as an antidepressant and the brand names Eskesia, Ketanest, Ketanest S, Ketanest-S, Keta-S for use as an anesthetic (veterinary), among others.

Controversy

The British critical psychiatrist Joanna Moncrieff has critiqued the use and study of esketamine and ketamine as well as related drugs like psychedelics for treatment of psychiatric disorders, highlighting concerns including excessive hype around these drugs, questionable biologically-based theories of benefit, blurred lines between medical and recreational use, flawed clinical trial findings, financial conflicts of interest, strong expectancy effects and large placebo responses, small and short-term benefits over placebo, and their potential for difficult experiences and adverse effects, among others.

Legal status

Esketamine is a Schedule III controlled substance in the United States.

Esketamine is a controlled drug In The United Arab Emirates due to its potential for abuse, its use is only under strict medical supervision which is only available on government hospitals in the country, and its use only approved for treatment-resistant depression registered under the trademark Spravato.

References

References

1. (12 May 2022). "Updates to the Prescribing Medicines in Pregnancy database".
2. (June 2022). "Craving and addictive potential of esketamine as side effects?". Expert Opinion on Drug Safety.
3. (17 March 2021). "Spravato".
4. (24 May 2021). "AusPAR: Esketamine hydrochloride".
5. Anvisa. (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
6. (23 October 2014). "Regulatory Decision Summary - Spravato -".
7. "Spravato 28 mg nasal spray, solution - Summary of Product Characteristics (SmPC)".
8. (21 February 2020). "Vesierra 25 mg/ml solution for injection/infusion - Summary of Product Characteristics (SmPC)".
9. (16 October 2019). "Spravato EPAR".
10. (6 August 2020). "Spravato- esketamine hydrochloride solution".
11. "Esketamin - Anwendung, Wirkung, Nebenwirkungen {{!}} Gelbe Liste".
12. (December 1998). "[The clinical use of S-(+)-ketamine--a determination of its place]". Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie.
13. (November 1998). "Ketamine: teaching an old drug new tricks". Anesthesia and Analgesia.
14. (April 2021). "Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment". Psychopharmacology (Berl).
15. (February 2021). "Ketamine: A tale of two enantiomers". J Psychopharmacol.
16. (June 2017). "Classics in Chemical Neuroscience: Ketamine". ACS Chem Neurosci.
17. (November 2020). "The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur". Can J Psychiatry.
18. (May 2020). "Are we repeating mistakes of the past? A review of the evidence for esketamine". Br J Psychiatry.
19. (December 2019). "Esketamine for treatment resistant depression: a trick of smoke and mirrors?". Epidemiol Psychiatr Sci.
20. (June 2021). "Consistently Modest Antidepressant Effects in Clinical Trials: the Role of Regulatory Requirements". Psychopharmacol Bull.
21. (December 2019). "Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval". Lancet Psychiatry.
22. (13 January 2020). "SPRAVATO™ Clinical Studies | Touchstone TMS".
23. (November 2021). "Interpretation of the Montgomery-Åsberg Depression Rating Scale (MADRS)". The British Journal of Psychiatry.
24. (December 2020). "The role of dissociation in ketamine's antidepressant effects". Nat Commun.
25. (May 2021). "Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation". Am J Psychiatry.
26. (September 2021). "Blinding and expectancy confounds in psychedelic randomized controlled trials". Expert Rev Clin Pharmacol.
27. (October 2021). "Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials". Expert Rev Clin Pharmacol.
28. (August 2021). "Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression in Adults: A Systematic Review". Cureus.
29. (August 2021). "Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review". Int J Mol Sci.
30. (2021). "Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior". J Clin Psychopharmacol.
31. (May 2018). "Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review". CNS Drugs.
32. (2020). "Esketamine/ketamine for treatment-resistant depression". Braz J Psychiatry.
33. (May 2017). "Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight". Lancet Psychiatry.
34. (July 2022). "Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review". Pharmacotherapy.
35. (September 2021). "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder". Cochrane Database Syst Rev.
36. (May 2021). "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status". CNS Drugs.
37. (March 2020). "Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study". J Affect Disord.
38. (January 2021). "Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis". J Affect Disord.
39. (March 2021). "Comments to Drs. Bahji, Vazquez, and Zarate". J Affect Disord.
40. (July 2020). "Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine". Biochem Pharmacol.
41. (May 2021). "Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor". Mol Psychiatry.
42. (12 February 2019). "First Big Depression Advance Since Prozac Nears FDA Approval.". [[Bloomberg News]].
43. (6 March 2019). "Why a ketamine-like drug is being used to treat depression".
44. Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee. (12 February 2019). "FDA Briefing Document". [[Food and Drug Administration]].
45. (28 January 2020). "Anti-depressant spray not recommended on NHS".
46. (10 September 2019). "J&J scores Spravato trial win in high-risk depression. Will doctors and payers buy in?".
47. (14 December 2022). "1 Recommendations | Esketamine nasal spray for treatment-resistant depression | Guidance | NICE".
48. (May 2021). "Intranasal esketamine: From origins to future implications in treatment-resistant depression". J Psychiatr Res.
49. (December 1998). "[The clinical use of S-(+)-ketamine--a determination of its place]". Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie.
50. (January 2014). "R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine". Pharmacology, Biochemistry, and Behavior.
51. (June 2016). "Ketamine enantiomers in the rapid and sustained antidepressant effects". Therapeutic Advances in Psychopharmacology.
52. (November 2016). "Ketamine's antidepressant action: beyond NMDA receptor inhibition". Expert Opinion on Therapeutic Targets.
53. (October 2016). "Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression". Psychopharmacology.
54. (October 1999). "Ketamine stereoselectively inhibits rat dopamine transporter". Neuroscience Letters.
55. (October 1992). "[Ketamine racemate or S-(+)-ketamine and midazolam. The effect on vigilance, efficacy and subjective findings]". Der Anaesthesist.
56. (November 1994). "[Psychometric changes as well as analgesic action and cardiovascular adverse effects of ketamine racemate versus s-(+)-ketamine in subanesthetic doses]". Der Anaesthesist.
57. (September 2015). "R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects". Translational Psychiatry.
58. (February 1997). "Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)". European Neuropsychopharmacology.
59. (15 February 2021). "The Nuances of Ketamine's Neurochemistry".
60. (November 2001). "Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine". Clinical Pharmacology and Therapeutics.
61. (May 2021). "Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation". The American Journal of Psychiatry.
62. (February 2025). "Ketamine and Esketamine in Clinical Trials: FDA-Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations". Clin Pharmacol Ther.
63. (August 2017). "Beyond serotonin: newer antidepressants in the future". Expert Review of Neurotherapeutics.
64. (March 2017). "Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression". Drugs.
65. "Esketamine - Johnson & Johnson - AdisInsight".
66. "Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression". Janssen Pharmaceuticals, Inc..
67. "FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic".
68. (4 August 2020). "FDA Approves A Nasal Spray To Treat Patients Who Are Suicidal". NPR.org.
69. (January 2020). "A Paradigm Shift for Depression Treatment". [[Kalmbach Media]].
70. (7 March 2019). "The FDA Approved a Ketamine-Like Nasal Spray for Hard-to-Treat Depression".
71. (25 October 2022). "Esketamine". Drugs.com.
72. Moncrieff, Joanna. (16 January 2025). "Chemically Imbalanced: The Making and Unmaking of the Serotonin Myth". Flint.
73. "'Breakthrough' nasal spray to treat depression coming to UAE".